Home Treatments New ProstAtak Clinical Trials

New ProstAtak Clinical Trials

Published on October 16, 2012, by in Treatments.

ProstAtak is a new prostate cancer treatment trial for localized prostate cancer using gene
therapy. This new cancer treatment trial is now available at our facilities and we are one of only two medical centers in the Houston area that offer this treatment trial.

Contact us today about participation in this new cancer treatment trial – 281.351.5174

The odds are already in your favor.

If you have been diagnosed with early or intermediate stage prostate cancer, there is every reason to be optimistic. Thanks to early testing, most prostate cancers are now found before symptoms appear, and treatment by radiotherapy or surgery will, in the majority of cases, lead to a cure.

Sometimes, however, the cancer comes back, even years after the initial treatment. This is called recurrence and it happens in about 30% of patients. At that point it may have spread beyond the prostate; treatment includes medical castration with hormones and chemotherapy, and the risk of treatment failure is considerably higher than before.

A Future Weapon Against Prostate Cancer Recurrence?

Today, doctors have a better understanding of cancer than ever before, and medical research is exploring new ways to prevent recurrence. For prostate cancer, a new drug candidate called ProstAtak has proven to be especially promising in early trials. In a Phase II study, the rate of recurrence was reduced from an expected 30% down to 10%.

The ProstAtak treatment works something like a vaccine. Based on an innovative technique known as gene transfer technology, it is used in conjunction with standard radiation therapy. The idea, basically, is to “jump-start” the body’s own immune system so it can detect and destroy remaining or recurring cancer cells. ProstAtak is not the only cancer vaccine, but at present it is the only vaccine product in development for preventing recurrence in newly diagnosed, localized prostate cancers. Like yours.

While the typical drug approval process can take many years, even decades, ProstAtak is already in its final stage of evaluation. Early test data on ProstAtak have been strong enough to merit so-called “Fast-track” designation and special FDA approval for an accelerated Phase III clinical trial.

If the outcome of this study is positive, ProstAtak is likely to be approved – the first drug ever with early stage prostate cancer as its primary indication.

We’re ready to get going. Now the only obstacle to completing this potentially life-saving study is finding qualified patients to participate.

This is Where You Come In.

Because you have prostate cancer, you may qualify to take part in this research study. Your doctor will discuss the details of the experimental treatment, which is done in addition to and together with your standard radiation therapy. It is important to remember that if you participate, you will receive the same standard of care treatment as you would if you do not participate. The only difference is the addition of the study drug being evaluated to prevent cancer recurrence.

There’s one other thing to remember. Because of the way a Phase III trial is setup, not all participants will receive ProstAtak. Everybody will receive the standard radiation therapy and two out of three men in this study will receive a ProstAtak; the other one-third will receive a placebo in addition to radiation therapy. Selection is random, and neither you, nor your doctor nor the sponsor of the study will know whether you are receiving ProstAtak or the placebo. If you are able to participate, you will receive the same care as otherwise – plus, there is a two-to-one chance you will be receiving ProstAtak.


Click here for more information

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>